Back to News
Market Impact: 0.25
CRISM Therapeutics Reports Wider H1 Loss As Phase 2 Programme Advances
Source: Nasdaq
Healthcare & BiotechCorporate EarningsCompany Fundamentals
CRISM Therapeutics reported an unaudited wider net loss for the six months ended June 30, 2026, versus the prior-year period. The company also issued a clinical update on its implantable biodegradable drug-related program, though the provided article excerpt does not disclose specific financial figures or trial results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.30
More News
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
- Costco is taking aim at its May record high — how it got here and where's it going
- As tech swoon roils market, US inflation data on tap
- FTSE 100 today: Stocks slump as global tech rout deepens
- Tesla is ‘winding down’ production of the Cybertruck next year
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom